Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 8:13 PM ET


Company Overview of Altor BioScience Corporation

Company Overview

Altor BioScience Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of immunotherapeutic agents for the treatment of cancer, viral infections, and inflammatory and autoimmune diseases. Its product candidates include ALT-801, a T-cell receptor-targeted immunotherapeutic for cancer; ALT-836, a monoclonal antibody-based tissue factor antagonist treatment of patients with acute respiratory distress syndrome and acute lung injury; and ALT-803, an IL-15 superagonist for patients with solid and hematological tumors/metastatic melanoma. The company’s product candidates also include ALT-802, a p53-TCR (T-cell receptors)/IgG1 fusion protein for treat...

2810 North Commerce Parkway

Miramar, FL 33025-3958

United States

Founded in 2002





Key Executives for Altor BioScience Corporation

Chief Executive Officer, President, and Director
Vice President of Research and Development
Chief Business Officer
Compensation as of Fiscal Year 2015.

Altor BioScience Corporation Key Developments

Altor BioScience Corporation Presents at BIO-Europe 2015, Nov-02-2015

Altor BioScience Corporation Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

Altor BioScience Corporation Presents at 2015 BioFlorida Annual Conference, Oct-12-2015 11:40 AM

Altor BioScience Corporation Presents at 2015 BioFlorida Annual Conference, Oct-12-2015 11:40 AM. Venue: Omni Orlando Resort at ChampionsGate, 1500 Masters Blvd, ChampionsGate, FL 33896, United States. Speakers: Hing C. Wong, Chief Executive Officer, President, and Director.

Altor BioScience Corporation Announces Efficacy and Safety of Alt-801 for Advanced Bladder Cancer at 2015 Asco Annual Meeting

Altor BioScience Corporation announced that it will present updated safety and efficacy data from its ongoing Phase 1b/2 study of ALT-801 in combination with gemcitabine and cisplatin in patients with advanced or metastatic chemo-refractory urothelial cancer. ALT-801 is a novel proprietary immunotherapy composed of IL-2 genetically fused to a soluble T-cell receptor directed against a p53-derived tumor associated antigen. Altor’s approach uses the TCR to guide IL-2 bioactivity to the tumor site, where the cytokine-stimulated immune system attacks the cancerous cells. ALT-801 exhibits a favorable pharmacokinetic and biodistribution profile, improved efficacy and lower toxicity compared to standard IL-2 treatment in various tumor efficacy models. In early phase clinical testing in patients with metastatic malignancies, ALT-801 was well tolerated in the out-patient setting at dose levels that provided treatment-induced immune responses and clinical benefit to patents. Altor has concluded two Phase 1/2 clinical studies of ALT-801 in combination with gemcitabine and cisplatin or gemcitabine alone in patients with advanced/metastatic urothelial cancer. Altor is also conducting a clinical trial of ALT-801 in combination with gemcitabine in patients with Bacillus Calmette Guerin (BCG)-resistant non-muscle-invasive bladder cancer.

Similar Private Companies By Industry

Company Name Region
Androclus Therapeutics, Inc. United States
T&L Pharmacies, Inc. United States
Sova Pharmaceuticals, Inc. United States
Avery Pharmaceuticals, Inc. United States
Biomagnetic Solutions, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Altor BioScience Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at